Clinical characteristics of infants diagnosed with cCMV infection
| Case | Gender | Maternal CMV infection type | Trimester of maternal infection | Suspicion during pregnancy | Sign/s at birth other than refer hearing screening | Saliva screening taken day | Urine screening taken day | Hearing status at diagnosis | Age at start of antiviral treatment, weeks |
| 1 | M | Non-primary | Unknown | No | No | 3 | 10 | Bilateral mild to moderate SNHL | 5 |
| 2 | F | Primary | 2 | Maternal seroconversion | No | 1 | 3 | Within normal range | 12* |
| 3 | F | Primary | 1 | Maternal seroconversion | Petechiae, LSV, germinal matrix cyst, SGA, symmetric IUGR | 2 | 6 | Bilateral profound SNHL | 2 |
| 4 | F | Non-primary | Unknown | No | LSV, germinal matrix cysts | 3 | 5 | Bilateral profound SNHL | 2 |
*Valganciclovir treatment initiated due to developmental delay.
cCMV, congenital cytomegalovirus; F, female; IUGR, intrauterine growth restriction; LSV, lenticulostriate vasculopathy; M, male; SGA, small for gestational age; SNHL, sensorineural hearing loss.